Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.
about
Management of Membranous Nephropathy in Western CountriesAntiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous NephropathyPhospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathySpontaneous remission of nephrotic syndrome in idiopathic membranous nephropathySmoking is a risk factor for the progression of idiopathic membranous nephropathy.Membranous nephropathy: a retrospective observational study of membranous nephropathy in north east and central London.Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis.Membranous nephropathy in children: clinical presentation and therapeutic approach.A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.Treatment of idiopathic membranous nephropathy (IMN).Controversies in the treatment of idiopathic membranous nephropathy.Myofibroblast: a prognostic marker and target cell in progressive renal disease.M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathyThe natural history of the non-nephrotic membranous nephropathy patient.Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathyLow-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathyA European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.Membranous Nephropathy: Quantifying Remission Duration on Outcome.Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease.Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.Resurgence of membranous nephropathy in African Americans in inner city Chicago.Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis.Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathyComparative evaluation of nephroprotective potential of resveratrol and piperine on nephrotic BALB/c mice.Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patientsLong-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategyMembranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.Novel biomarkers in glomerular disease.Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.Management of idiopathic membranous nephropathy.Glomerular diseases: membranous nephropathy--a modern viewOut of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town.Membranous nephropathy: thinking through the therapeutic options.A Proposal for a Serology-Based Approach to Membranous Nephropathy.Treatment of membranous nephropathy: time for a paradigm shift.Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
P2860
Q26740477-FA00B277-BDBF-4485-B06C-28D98446C17BQ27023372-D0FA0469-632E-4060-BB4E-EF21A36CC162Q33660542-F79B9A00-5BA2-4F51-B5EE-03D88E4534C3Q33748541-F06B8CA4-41DC-4FEB-B804-78EBA50D73AFQ33806897-A30CCA09-8BA0-49FA-84E4-41F9BB6C8FC0Q33823525-E75943A2-CC13-4953-8493-7680EFC8085CQ33894748-638F84CE-FBEE-4798-8D13-93EC6B2B3EFFQ33920367-365A1C67-D496-476D-A628-D98E8F1A2ECEQ33932604-41CD8647-808A-44DC-8D24-2D221A8BA9DCQ34097222-21C308E1-6D72-462F-8F8B-58104B382831Q34248343-FD43B626-19A3-4CB5-AD48-10C16715232FQ34333429-2C8D4AAC-DF62-4D0D-82E5-B4466281A093Q34455214-96917FBE-EF27-4537-8559-7C2235437BABQ34658973-48D7AABD-CBED-4607-A7CD-261FB04895B5Q34701007-539D895C-E8B8-44D4-96E1-28FD2CA959BCQ35433416-01FAE56B-D484-4CED-8CE7-B48C0AFAE9DBQ35664611-F2B89816-5E2D-456B-8282-904E72B71DAAQ36088887-02313B7B-025E-4E33-8662-93DE670920C0Q36126897-0B2A4A8F-2F4A-40DA-B1ED-5EB53C40D6F5Q36167127-FDCFBB93-1D48-4A80-9BD3-0B8ECBB77EFFQ36196571-2294BC9C-A8D6-4289-8F39-583458A25C3CQ36728772-AAF0564D-6A81-4C32-AAAF-13811FBC5327Q36741001-1743742F-D989-4E23-A85B-3EA24CB15013Q36849177-37EE909B-0986-440C-B6BB-29333CCA487CQ36982075-15EFCC53-25B2-4B15-9B6A-E1891888B6E4Q37087861-0BF8CE00-A730-4338-828D-3C2C6B55EC9EQ37146440-ED96136A-8F7D-43A1-8FEF-267A43E65377Q37167305-25FB8ED5-ECAE-426A-93AC-4EE725BCF7E4Q37211086-9787DB56-A729-4EB6-A31F-92D349AA252FQ37411651-A069AEB0-867B-410B-9BA7-0884D7BDE6D4Q37475696-06079921-2FE6-4A92-B9A8-9CA0EACB7EE1Q37658483-79E1E177-926B-4340-8A52-57BAA164C8D9Q37665145-B59B2500-D3E0-4818-88BA-E9FCD18C19FDQ37779802-CCCDDB1E-B3F1-44C4-88EF-D6354D7E3317Q38118221-DA4FA3A2-1452-4C23-97AA-8AE5592C7EF2Q38680011-882AE3F4-FFE5-4EB8-BB7C-553477A55FD1Q38733002-848D81D9-6E21-45D4-B9E0-4016D6B101AAQ38989854-CE0C8EA0-BC19-4ACB-8320-4FAB9A014C30Q39410091-BDC0F9FE-A3FC-47AC-BC4A-ECD12CF0DCB2Q40663445-A5356592-8722-40ED-AD47-3DB62B8E366B
P2860
Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Validation of a predictive mod ...... cal and research implications.
@en
Validation of a predictive mod ...... cal and research implications.
@nl
type
label
Validation of a predictive mod ...... cal and research implications.
@en
Validation of a predictive mod ...... cal and research implications.
@nl
prefLabel
Validation of a predictive mod ...... cal and research implications.
@en
Validation of a predictive mod ...... cal and research implications.
@nl
P2093
P356
P1433
P1476
Validation of a predictive mod ...... cal and research implications.
@en
P2093
Cattran DC
Greenwood CM
Honkanen E
Passerini P
Ponticelli C
P2888
P304
P356
10.1038/KI.1997.127
P407
P577
1997-03-01T00:00:00Z
P5875
P6179
1038373905